Comisión de Evaluación de medicamentos.
4. Verzegnassi F, Chinello M (2010) Exenatide in type 2 diabetes. Lancet 376 (9746): 1052¬
1053.
5. Peters A (2010) Incretin-based therapies: review of current clinical trial data. Am J Med 123 (3 Suppl): S28-S37.
6. Wajcberg E, Tavaria A (2009) Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 10 (1): 135-142.
7. Segal JB, Dy SM, Millman EA, Herbert R, Bass EB, Wu A (2007) Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy. Clin Ther 29 (8): 1784-1794.
8. Philippe J (2009) Role and indication of GLP-1 analogues in the treatment of type 2 diabetes. Rev Med Suisse 5 (206): 1260-1262, 1264-1265.
9. Reuter H, Erdmann E (2007) Exenatide–an incretin-mimetic agent for the treatment of type 2 diabetes mellitus. Dtsch Med Wochenschr 132 (11): 571-574.
10. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (8): 1963-1972.
11. Schernthaner G, Barnett AH, Betteridge DJ, Carmena R, Ceriello A, Charbonnel B, et al (2010) Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 53 (7): 1258-1269.
12. German Diabetes Association, Matthaei S, Bierwirth R, Fritsche A, Gallwitz B, Häring HU, et al (2009) Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 117: 522–557.
13. Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, et al (2010) Effects
of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 123 (5): 468.e9-17.
14. Robles GI, Singh-Franco D (2009) A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Des Devel Ther 3: 219-240.
15. Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, et al (2010) Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 9: 6.
16. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al (2008) Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30: 1448-1460.
17. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24: 275-286.
18. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, , DURATION-1 Study Group, et al (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372: 1240-1250.
19. Okerson T, Yan P, Stonehouse A, Brodows R, Bhole D (2008) Exenatide improved systolic blood pressure compared to insulin or placebo in patients with type 2 diabetes. Diabetologia
51: S350.
20. Bergenstal R, Kim T, Yan P, Darsow T, Walsh B, Okerson T, et al (2009) Exenatide once weekly improved cardiometabolic risk factors in subjects with type 2 diabetes during one
year of treatment. Diabetes 58: A43.
21. Bhushan R, Elkind-Hirsch KE, Bhushan M, Butler WJ, Duncan K, Marrioneaux O (2009)
Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes Technol Ther 11 (6): 353-359.
22. Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP, et al (2008) Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol 48: 1389-1399.
23. Linnebjerg H, Kothare P, Park S, Mace K, Mitchell M (2009) The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. Int J Clin Pharmacol Ther 47 (11): 651-658.
24. Menéndez Torre E, Lafita Tejedor J, Artola Menéndez S, Millán Núñez-Cortés J, Alonso García Á, Puig Domingo M, et al (2010) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Av Diabetolo 26: 331-338.
25. Svec F (2010) Incretin physiology and its role in type 2 diabetes mellitus. J Am Osteopath Assoc 110 (7 Suppl 7): eS20-24.
26. Sudhakaran C, Fathima M, Anjana RM, Unnikrishnan RI, Mohan V (2010) Effectiveness of exenatide in Asian Indians in a clinical care setting. Diabetes Technol Ther 12 (8): 613-618.
27. Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al (2010) Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375 (9733): 2234-2243.
28. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, et al; DURATION-2 Study Group (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376 (9739): 431-439.
29. Blevins T, Han J, Nicewarner D, Chen S, Oliveira JH, Aronoff S (2010) Exenatide is non-
inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med 122 (3): 118-128.
30. Natarajan B, Edavalath M, Davies J, Jenkins L, Marshall-Richards N, Evans D, et al (2010) Clinical experience with exenatide in a routine secondary care diabetes clinic. Prim Care Diabetes 4 (1): 57-60.
31. Yoon NM, Cavaghan MK, Brunelle RL, Roach P (2009) Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 31 (7): 1511-1523.
32. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al; DURATION¬1 Study Group (2008) Exenatide once weekly versus twice daily for the treatment of type 2